Full Text View
Tabular View
No Study Results Posted
Related Studies
Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients
This study is currently recruiting participants.
Study NCT00304694   Information provided by National Taiwan University Hospital
First Received: March 16, 2006   No Changes Posted

March 16, 2006
March 16, 2006
March 2006
 
 
 
No Changes Posted
 
 
 
Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients
Whole-Body 18F-FDG PET in Evaluating Induction Chemotherapeutic Response for Locally Advanced Nasopharyngeal Cancer Patients and Correlating With Histopathology: a Prospective Study

18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches.

We propose to conduct a prospective study to evaluate therapeutic response using 18F-FDG PET before and after induction chemotherapy for locally advanced NPC patients.

In order to improve locoregional control and to eradicate micrometastases for patients with locally advanced nasopharyngeal carcinoma (NPC), induction chemotherapy followed by concurrent chemoradiotherapy has been the preferred therapeutic approach.Although it would be of great advantage to identify non-responder during or immediately after therapy to formulate an alternative treatment strategy, non-invasive methods for early evaluation of therapeutic response for advanced NPC patients have not been fully evaluated. Decrease of tumor volume in anatomical images and relief of symptoms in clinical follow-up have been used in many conventional approaches to evaluate the effectiveness of therapy. However, an effective therapy could very well have resulted in early subclinical alterations in tumor physiology and biochemistry. These alterations may have occurred long before changes in the tumor mass become apparent. Thus therapeutic effect may not be assessed accurately using the conventional anatomical imaging studies, such as CT and MRI.Recent studies have shown that 18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches.We therefore propose to conduct a prospective study to evaluate therapeutic response using 18F-FDG PET before and after induction chemotherapy for locally advanced NPC patients.

 
Observational
Screening, Cross-Sectional, Convenience Sample, Prospective Study
Nasopharyngeal Cancer
 
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
50
 
 

Inclusion Criteria:

  • newly diagnosed locally advanced NPC patients who are receiving induction chemotherapy for treatment

Exclusion Criteria:

  • age below 18 year old
  • pregnancy women
Both
18 Years to 80 Years
No
Contact: Ruoh-Fang Yen, MD, PhD 886-2-23123456 ext 5581 rfyen@ha.mc.ntu.edu.tw
Taiwan
 
NCT00304694
 
940601
National Taiwan University Hospital
 
Principal Investigator: Ruoh-Fang Yen, MD, PhD National Taiwan University Hospital
National Taiwan University Hospital
March 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP